BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]
BeOne Medicines Ltd. - American Depositary Shares (ONC)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points BeOne Medicines Ltd ( NASDAQ:ONC ) achieved significant product revenue growth, GAAP profitability, and meaningful cash flow generation in 2025. Brukinza, their foundational BTK inhibitor, became the number one product both in the US and globally, setting a new standard for efficacy and safety in CLL. The company reported a 32% year-over-year growth in product revenue for Q4 2025, with Brukinza's global revenues growing by 49% for the full year. BeOne Medicines Ltd ( NASDAQ:ONC ) has a strong pipeline with multiple assets achieving clinical proof of concept and advancing towards registration. The company is expanding its leadership in CLL and other hematological malignancies, with plans to establish itself as an oncology powerhouse in solid tumors. Negative Points The fixed dura
Show less
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeOne Medicines Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its price target raised by Barclays PLC from $394.00 to $405.00. They now have an "overweight" rating on the stock.MarketBeat
- BeOne Medicines (ONC) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology LeadershipBusiness Wire
ONC
Earnings
- 2/26/26 - Beat
ONC
Sec Filings
- 2/6/26 - Form 4
- 1/9/26 - Form 4
- 1/5/26 - Form 4
- ONC's page on the SEC website